MSD and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies

Save

January 28, 2022 6:45 am ET

Click here to read the news release